4
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
4
Rare Diseases
across 9 areas
0
News (30d)
Quiet
Insys Development Company, Inc. is a company with 4 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Dravet syndrome | cannabidiol | Des.TrialAppr. |
| Lennox-Gastaut syndrome | cannabidiol | Des.TrialAppr. |
| idiopathic pulmonary fibrosis | Cintredekin Besudotox | Des.TrialAppr. |
| malignant glioma | cintredekin besudotox | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
11
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
11
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio